U.S. Markets open in 7 hrs 5 mins

Apricus Biosciences, Inc. (APRI)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.09+0.08 (+7.92%)
At close: 4:00PM EDT
People also watch
BIOCETRMANTHPULMIDXG
  • Monster MicroCaps SPECIAL ALERT to APRI shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
    finance.yahoo.com
  • Pascoe time to derliver, you said you'd hear from the FDA by 2nd quarter about Vitaros U.S. well one week left, deliver or i add it to your endless list of 'fibs? wrongfullness......?
  • I just wonder one thing.. will I get TUMORS on my WeeWee from APRI Cream like experimental mice in that study? Why did FDA Deny??... Tumors on mice WeeWees?? What's the real story here??
  • IGXT (MC $46 M)US-NDA Submission for BLOCKBUSTER Drug this month =1000%+ Upside Potential ! PLEASE READ THIS

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • Any reason for this uptick?
  • The Typed words within this post is/are just Speculative thinking on my part,and I may be 100% incorrect and so take it as speculation only and not fact?
    I cant help, but to wonder, if the move in the Share price today with volume,is due to bad News? such as a Reverse/Split?maybe information about a proposed Reverse/Split,was leaked ,and knowing that a Reverse/Split, is a Negative event, generally, and causes the Share price to decline once a Press/Release is made public, and so for that reason they inflate the Share price allowing some to liquidate their positions at higher prices before the Bad News hits the street VIA a Public P/R? PS if anyone has any information as to the reason for the increase in Share price please replay
  • Is pascoe going to finally keep a promise about FDA decsion on Room Temperature Device this June? he said he should hear back from the FDA by Q2 that means only June is left in Q2 and we are in June!!!!!
  • BOD has got to wake up and make an example of pascoe for all his errors in judgement to date, imo, get rid of the guy, Trump would have told him years ago, "You are fired"!!!"
  • think about it, us shareholders paid $50M for fispemiphene 3 years ago. a drug that sat on the shelves since 2005? and pascoe rushes in to buy all U.S. rights from a near bankrupt European company, only to discover the reason no one else wanted to buy it..it was a total failure. Why is Pascoe still here?
  • "discontinued operations" means all outside Vitaros sales sold for a measly $12M when we were told Vitaros sales were doubling and doing 'great' in Europe....remember the CEO of Majorelle bailed pascoe out of another lie about a Abbott Vitaros soon to launch in Canada but the CEO of Majorelle said how great Vitaros would do in Eyrope and France.. so we let Pascoe slide under the carpet like the lsithering snake he is, imo..so to date NEXM now APRI paid over $400M to develop all Vitaros products and they sell al outside U.S. rights for $12m?
    sounds like pascoe just wants to milk this sinking ship for every penny he can cause he knows he will never be a CEO ever again after APRI fails, imo, and also not afte his r SOMX's disaster and slow bleed.....which he was 100% responsible for....
  • huge upside get ready for the mega run vitaros is approved by the FDA to US sale's
  • This is a sinking ship...for the past 5 years....
  • Next up...another reverse split....watch your shares go away....
  • PUMP!!!!!!!!!!!!!!!!!
  • Volume and upward price today
  • whats going on with this stock. is this a buy ahead of earnings?
  • RALLYYYYYYYYYYYYYYYYYYY
    BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 20 BAGGER POTENTIAL !!!
    AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 11 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.18

    MUST WATCH to realize the MONSTER POTENTIAL HERE
    https://www.dukascopy.com/tv/en/view/204408#00

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

  • I'm certain the share price will come back up. I think this was a sell on news sort of situation. I imagine it being around 1.40 next week eventually
  • welp... it wasn't a beat. but at least you guys didn't lose. soooo, congrats!
  • Today is the day!